Dr. Cameron Pole, M.D.
Ophthalmology (Ophthalmology Physician)
1450 San Pablo St Fl 4
Los Angeles, CA 90033
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Miami, Lm Miller School of Medicine (2016)
- Years since graduation
- 10
- In the NPI registry since
- 2016
- Medicare patients seen, 2024
- 1,643
Licensed in California since 2017, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Medical school: University of Miami, Lm Miller School of Medicine
- 2016Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
CA license A151860 (first issued 2017; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mercy General Hospital Sacramento, CA
Medical groups
- Vitreo-Retinal Medical Group, Inc. (22 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,643
- Services billed
- 51,780
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 29,940 | 168 |
| Imaging of retina | 4,310 | 2,080 |
| Injection, aflibercept, 1 mg | 2,994 | 525 |
| Injection of drug into eye | 2,503 | 959 |
| Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | 1,610 | 99 |
| Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 983 | 95 |
| Established patient problem focused exam of visual system | 841 | 614 |
| Established patient complete exam of visual system | 675 | 574 |
| Injection, ranibizumab, 0.1 mg | 561 | 70 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 517 | 509 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Los Angeles, CA | 231 |
| Ofloxacin Other prescribers in Los Angeles, CA | 135 |
| Brimonidine Tartrate Other prescribers in Los Angeles, CA | 110 |
| Ketorolac Tromethamine Other prescribers in Los Angeles, CA | 91 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Los Angeles, CA | 73 |
| Latanoprost Other prescribers in Los Angeles, CA | 64 |
| Dorzolamide Hcl Other prescribers in Los Angeles, CA | 25 |
| Timolol Maleate Other prescribers in Los Angeles, CA | 22 |
| Bromfenac Sodium | 18 |
| Difluprednate | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 29 payments worth $1,079 in total to this clinician.
| Apellis Pharmaceuticals, Inc. | $192 |
|---|---|
| Harrow Eye, LLC | $142 |
| Genentech USA, Inc. | $140 |
| AbbVie Inc. | $119 |
| Neurotech Pharmaceuticals, Inc. | $110 |
| Astellas Pharma US Inc | $78.63 |
| Regeneron Healthcare Solutions, Inc. | $65.45 |
| Regeneron Pharmaceuticals, Inc. | $61.03 |
| Food and Beverage | $1,079 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $46,753 in research payments for these studies, mostly to the institutions running them.
- A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.